The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
one of the huge challenges of studying psychedelics is it's very difficult to Blind anybody most of all the user right the subject you know when you one group is getting psilocybin and the other group is getting even if it's niacin which causes some flushing you know it's it's it's not hard to know which group you're in and that may affect the results
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
one of the huge challenges of studying psychedelics is it's very difficult to Blind anybody most of all the user right the subject you know when you one group is getting psilocybin and the other group is getting even if it's niacin which causes some flushing you know it's it's it's not hard to know which group you're in and that may affect the results
one of the huge challenges of studying psychedelics is it's very difficult to Blind anybody most of all the user right the subject you know when you one group is getting psilocybin and the other group is getting even if it's niacin which causes some flushing you know it's it's it's not hard to know which group you're in and that may affect the results
And one of the dilemmas in doing research with any psychoactive drug but in particular the hallucinogens is that these doses, of course, are discriminable. People, they produce marked changes in consciousness and conscious experience. And so then the question becomes, so how do you run a double-blind study under these conditions?